What is the main business of Ośrodek Badań Farmaceutycznych i Klinicznych Biofana?

The main business activity of Ośrodek Badań Farmaceutycznych i Klinicznych Biofana focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on October 28, 2003.

Where is the headquarters located?

The headquarters is located at: Przytorze 1, 99-300 Kutno.

What is the share capital?

The share capital of the company is PLN 160,000 (approx. $43,220).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

How much revenue was generated?

In 2024, the company generated total revenue of $2,789,701, representing a decrease of 20.2% compared to 2023.

Is the company profitable?

No, in 2024 the company was not profitable, reporting a net loss of $476,962. For comparison, in 2023 the loss was $86,395, meaning the company increased its loss by 424.3%.

What is the main operating cost?

The largest operating cost category falls under employee remuneration. This category amounted to $1,427,093 in 2024, representing 48% of all operating expenses.

Ośrodek Badań Farmaceutycznych i Klinicznych Biofanasp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2003-10-28

Share capital

160 000,00 PLN

Registered address

Przytorze 1, 99-300 Kutno, Poland

Electronic delivery address

AE:PL-63650-34249-ADARW-26

Financials

Revenue history (in k)

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 4.22mMedianUSD 38.31kAverageUSD 2.31m

Net profit

This companyUSD 146.01kMedianUSD -1.50kAverageUSD -84.98k

Operating costs

This companyUSD 2.67mMedianUSD 56.25kAverageUSD 2.29m

Assets

This companyUSD 2.51mMedianUSD 116.77kAverageUSD 2.72m

Industry

Bank accounts

Registered as a VAT taxpayer on 2003-12-01. Active

BNP Paribas Bank Polska
40 1600 1462 1016 7910 6000 0005
BNP Paribas Bank Polska
67 1600 1462 1016 7910 6000 0004
ING Bank Śląski
57 1050 1461 1000 0090 3058 4925

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Public aid

4 public aid cases recorded, with a total value of $355,540.

Grant date	Purpose	Gross amount	Granting body
Jan 19, 2023	Aid for research and development projects: industrial research	$294.3K$294,269	Prezes Agencji Badań Medycznych
Jan 19, 2023	Aid for research and development projects: experimental development	$24,743$24,743	Prezes Agencji Badań Medycznych
Dec 27, 2022	Aid for research and development projects: industrial research	$36,528$36,528	Prezes Agencji Badań Medycznych

Tenders

No recorded participation in tenders.

Authorized Representatives

Jarosław Kazimierz Walczak — President

Marek Piotr Wośko — Attorney-in-fact (sole)

Manner of representation

A member of the management board acting individually.

Ownership

Owner	Shares	Share value	Stake
Agnieszka Katarzyna Erlach (65)	40	$10,804.97	17.7778%
Polfarmex S.A.	105	$28,363.05	46.6667%
Halina Regina Wośko (89)	40	$10,804.97	17.7778%
Marek Piotr Wośko (61)	40	$10,804.97	17.7778%

Beneficial owners

Person	Rights
Marek Piotr Wośko (61)	Posiada 52% akcji w spółce polfarmex s.a. , która posiada 65,63% udziałów w spółce biofana sp. z o.o.

Competitors

Name	Revenue	Website
MedappS.A.	$3,351,163.61	medapp.pl
BiotechnaS.A.	$2,472,888.07	bsbiotechna.com
Read-GeneS.A.	$2,163,474.84	read-gene.com
Proteon PharmaceuticalsS.A.	$2,026,826.52	proteonpharmaspolkaakcyjna.pl
SkinlabP.S.A.	$1,797,229.06	skinlab.pl
EIT Rawmaterials Clc Eastsp. z o.o.	$1,795,803.10	eitrawmaterials.eu
RDLSsp. z o.o.	$1,680,515.32	rdls.pl
Centrum Badań Weterynaryjnych Vetcomplexsp. z o.o.	$255,522.81	vetcomplex.pl
UveraS.A.	$155,384.29	uvera.eu
Luna Laboratorysp. z o.o.	$61,894.23	lunalab.pl

Change history

Date	Event
2022-03-14	Share capital change (60,000.00 PLN → 160,000.00 PLN)
2016-01-22	PKD change (Removed: 10.89.Z, 18.12.Z, 20.14.Z, 20.41.Z, 22.22.Z, 46.18.Z, 46.45.Z, 46.75.Z, 47.73.Z, 47.74.Z, 47.75.Z, 55.10.Z, 55.20.Z, 56.10.A, 56.10.B, 58.19.Z, 68.20.Z, 73.11.Z, 73.20.Z, 85.60.Z)
2010-09-22	PKD change (Added: 46.76.Z, 55.20.Z, 56.10.B, 58.19.Z, 68.20.Z, 72.11.Z, 85.60.Z)
2010-07-20	PKD change (Removed: 15.88.Z, 15.89.Z, 24.14.Z, 24.41.Z, 24.42.Z, 24.51.Z, 24.52.Z, 24.66.Z, 25.22.Z, 51.18.Z, 51.45.Z, 51.46.Z, 51.55.Z, 52.31.Z, 52.32.Z, 52.33.Z, 55.11.Z, 55.12.Z, 55.30.A, 73.10.F, 74.13.Z, 74.40.Z, 85.14.D; Added: 10.86.Z, 10.89.Z, 18.12.Z, 20.14.Z, 20.41.Z, 20.42.Z, 20.59.Z, 21.10.Z, 21.20.Z, 46.18.Z, 46.45.Z, 46.46.Z, 46.75.Z, 47.73.Z, 47.74.Z, 47.75.Z, 55.10.Z, 56.10.A, 72.19.Z, 73.11.Z, 73.20.Z, 86.90.E)
2004-06-04	Share capital change (50,000.00 PLN → 60,000.00 PLN)

FAQ

Last updated: 2026-07-06